An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.

Yamamoto N, Kenmotsu H, Goto K, Takeda K, Kato T, Takeda M, Horinouchi H, Saito I, Sarashina A, Tanaka T, Morsli N, Nakagawa K.

Open source

DOI: 10.1007/s00280-018-3649-x
Published: 2018-08-03
Container: Cancer Chemother Pharmacol
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00280-018-3649-x,
  title = {An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.},
  author = {Yamamoto N and  Kenmotsu H and  Goto K and  Takeda K and  Kato T and  Takeda M and  Horinouchi H and  Saito I and  Sarashina A and  Tanaka T and  Morsli N and  Nakagawa K.},
  year = {2018},
  journal = {Cancer Chemother Pharmacol},
  doi = {10.1007/s00280-018-3649-x},
  url = {https://doi.org/10.1007/s00280-018-3649-x}
}

RIS

TY  - JOUR
TI  - An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.
AU  - Yamamoto N
AU  -  Kenmotsu H
AU  -  Goto K
AU  -  Takeda K
AU  -  Kato T
AU  -  Takeda M
AU  -  Horinouchi H
AU  -  Saito I
AU  -  Sarashina A
AU  -  Tanaka T
AU  -  Morsli N
AU  -  Nakagawa K.
PY  - 2018
JO  - Cancer Chemother Pharmacol
DO  - 10.1007/s00280-018-3649-x
UR  - https://doi.org/10.1007/s00280-018-3649-x
ER  -

APA

N, Y., H, K., K, G., K, T., T, K., M, T., H, H., I, S., A, S., T, T., N, M., & K., N. (2018). An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-018-3649-x

Source records

europe-pmc · retrieved 2026-09-27T12:25:42.601Z